NBCD is a full-service CRO specialized in osteoarthritis, and we have conducted numerous OA trials in all clinical phases. We are dedicated to developing drugs for treatment of OA and specialize in trial design and execution of clinical trials within both OA pain and DMOAD compounds.
We are experts in placebo response mitigation and selecting the right patients for our partners and our legacy from Nordic Bioscience means that we have great experience with precision medicine using unique biomarker technologies to enhance drug development at all stages.
During the past 15 years, NBCD has successfully managed all aspects of several phase I, II and III trials within musculoskeletal conditions including osteoarthritis, osteoporosis, and rheumatoid arthritis. In total, more than 15,000 subjects have been enrolled in our trials worldwide.
We have been successfully inspected by FDA, EMA and other national European agencies, and we have taken part of and led large clinical projects to FDA approvals. Recent examples include the pivotal phase 3 program of Zilretta® for OA pain and the pivotal phase 3 program of abaloparatide for osteoporosis.
Our core competencies are:
Our approach is partner-centric, and we tailor our solutions to your specific needs. Our expertise allows us to provide you with a fixed budget and timeline, which relieves you from change orders and recruitment delays.
© 2025 blueskincro.com
